← All companies ← SVREW Manual SY → ← SVRA Pharmaceuticals TAK →
SXTC, China SXT Pharmaceuticals Inc.
A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn. Net current asset value. Current assets alone exceed every liability combined, and the surplus is most of the balance sheet: the shape Graham called a net-net.
- What moves the needle
- Operating margin has reached 33% at its best but run negative through the cycle (median −130%) on a 47% gross margin — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Inventory runs near 27% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median −58%, above 15% in 3 of 8 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2017–2026
realized figures from each filing · older years to the left| 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | 2026’26 | TTMTTMMar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| $5M | $7M | $7M | $5M | $5M | $3M | $2M | $2M | $2M | $1M | $1M | RevenueRevenue |
| 47% | 48% | 66% | 52% | 59% | 48% | 22% | 29% | 21% | 22% | — | Gross marginGross mgn |
| $2M | $2M | $2M | ($1M) | ($2M) | ($5M) | ($6M) | ($3M) | ($3M) | ($7M) | ($7M) | Operating incomeOp. inc. |
| 32.8% | 23.3% | 25.2% | −26.0% | −46.0% | −199.4% | −284.4% | −130.4% | −154.0% | −625.9% | −625.9% | Operating marginOp. mgn |
| $1M | $1M | $2M | ($10M) | ($3M) | ($6M) | ($6M) | ($3M) | ($3M) | ($6M) | ($4M) | Net incomeNet inc. |
| 25% | 27% | 14% | — | — | — | — | — | — | — | — | Effective tax rateTax rate |
| Cash flow & returns | |||||||||||
| $293K | $2M | $239K | $934K | ($1M) | $268K | ($81K) | ($2M) | ($2M) | ($4M) | ($4M) | Operating cash flowOp. cash |
| $94K | $129K | $181K | $332K | $345K | $320K | $250K | $203K | $82K | $74K | $74K | DepreciationDeprec. |
| ($987K) | $603K | ($1M) | $11M | $1M | $6M | $6M | $967K | $876K | $2M | $48K | Working capital & otherWC & other |
| $179K | $436K | $536K | $131K | $78K | $61K | — | $7K | $2K | — | $2K | CapexCapex |
| 3.7% | 6.2% | 7.6% | 2.5% | 1.6% | 2.3% | — | 0.4% | 0.1% | — | 0.2% | Capex / revenueCapex/rev |
| $114K | $1M | ($297K) | $803K | ($1M) | $207K | — | ($2M) | ($2M) | — | ($4M) | Owner earningsOwner earn. |
| 2.3% | 21.1% | −4.2% | 15.6% | −29.2% | 8.0% | — | −100.3% | −134.8% | — | −353.2% | Owner earnings marginOE mgn |
| $114K | $1M | ($297K) | $803K | ($1M) | $207K | — | ($2M) | ($2M) | — | ($4M) | Free cash flowFCF |
| 2.3% | 21.1% | −4.2% | 15.6% | −29.2% | 8.0% | — | −100.3% | −134.8% | — | −353.2% | Free cash flow marginFCF mgn |
| 67% | 45% | 82% | -49% | -67% | -719% | — | -99% | — | -259% | -258% | ROICROIC |
| 64% | 36% | 14% | -109% | -17% | -36% | -40% | -22% | -21% | -21% | -14% | Return on equityROE |
| 64% | 36% | 14% | −109% | −17% | −36% | −40% | −22% | −21% | −21% | −14% | Retained to equityRetained/eq |
| Balance sheet | |||||||||||
| $66K | $658K | $9M | $7M | $13M | $16M | $17M | $12M | $18M | $28M | $28M | Cash & investmentsCash+inv |
| — | $3M | $4M | $4M | $5M | $3M | $1M | $1M | $1M | $932K | $932K | ReceivablesReceiv. |
| — | $1M | $1M | $893K | $860K | $1M | $531K | $795K | $828K | $777K | $777K | InventoryInvent. |
| — | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $498K | $498K | Accounts payablePayables |
| — | $1M | $4M | $3M | $4M | $3M | $498K | $830K | $971K | $1M | $1M | Operating working capitalOper. WC |
| — | $6M | $16M | $20M | $23M | $22M | $20M | $14M | $21M | $35M | $35M | Current assetsCur. assets |
| — | $4M | $6M | $12M | $19M | $17M | $14M | $9M | $6M | $4M | $4M | Current liabilitiesCur. liab. |
| — | 1.4× | 2.5× | 1.6× | 1.3× | 1.3× | 1.3× | 1.6× | 3.5× | 7.9× | 7.9× | Current ratioCurr. ratio |
| — | $8M | $17M | $22M | $35M | $34M | $30M | $23M | $22M | $35M | $35M | Total assetsAssets |
| — | — | $42K | $37K | $6K | $11K | $126K | $138K | $105K | $644K | $649K | Total debtDebt |
| — | — | ($9M) | ($7M) | ($13M) | ($16M) | ($17M) | ($12M) | ($18M) | ($28M) | ($28M) | Net debt / (cash)Net debt |
| 39.7× | 2095.3× | 342.0× | -0.4× | -1.4× | -141.4× | -11.8× | -4.6× | -4.1× | -113.1× | -16.6× | Interest coverageInt. cov. |
| $2M | $3M | $11M | $9M | $16M | $16M | $15M | $14M | $15M | $30M | $30M | Shareholders’ equityEquity |
| Per share | |||||||||||
| 6.7M | 6.7M | 6.9M | 6.2M | 720K | 41.6M | 33K | 1K | 9.5M | 680K | 92K | Shares out (diluted)Shares |
| $0.73 | $1.05 | $1.02 | $0.84 | $6.64 | $0.06 | $59.08 | $2667.35 | $0.18 | $1.67 | $12.40 | Revenue / shareRev/sh |
| $0.18 | $0.18 | $0.22 | $-1.66 | $-3.82 | $-0.14 | $-177.84 | $-4285.66 | $-0.35 | $-9.13 | $-45.11 | EPS (diluted)EPS |
| $0.02 | $0.22 | $-0.04 | $0.13 | $-1.94 | $0.00 | — | $-2676.51 | $-0.25 | — | $-43.81 | Owner earnings / shareOE/sh |
| $0.02 | $0.22 | $-0.04 | $0.13 | $-1.94 | $0.00 | — | $-2676.51 | $-0.25 | — | $-43.81 | Free cash flow / shareFCF/sh |
| $0.03 | $0.07 | $0.08 | $0.02 | $0.11 | $0.00 | — | $9.77 | $0.00 | — | $0.02 | Cap. spending / shareCapex/sh |
| $0.28 | $0.49 | $1.62 | $1.52 | $22.18 | $0.39 | $440.23 | $19267.56 | $1.63 | $43.71 | $323.77 | Book value / shareBVPS |
Share counts before 2020 are restated ×1/3 for a stock split, so per-share figures sit on one basis.
The diluted share count moved ×1/8.59 into 2021 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×57.8 into 2022 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×1/1246.28 into 2023 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×1/46.16 into 2024 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×13124.48 into 2025 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×1/13.96 into 2026 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.
The diluted share count moved ×1/7.41 into TTM — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +9.6%/yr | −24.1%/yr |
| Capital spending / share | −45.4%/yr (8-yr) | −60.1%/yr |
| Book value / share | +75.4%/yr | +14.5%/yr |
The record, charted
FY2017–2026Each measure over its full record; the current point and the worst year marked. Share counts on the current split basis.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedEach year's operating cash, by what management did with it: the mix, and how it drifts.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned a $3M loss into ($2M) of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|
| Reported net income | ($3M) | ($3M) | ($6M) | ($3M) | ($10M) |
| Depreciation & amortizationnon-cash charge added back | +$82K | +$203K | +$320K | +$345K | +$332K |
| Working capital & othertiming of cash in and out, other non-cash items | +$876K | +$967K | +$6M | +$1M | +$11M |
| Cash from operations | ($2M) | ($2M) | $268K | ($1M) | $934K |
| Capital expenditurecash put back in to keep running and to grow | −$2K | −$7K | −$61K | −$78K | −$131K |
| Owner earnings | ($2M) | ($2M) | $207K | ($1M) | $803K |
| Owner-earnings marginowner earnings ÷ revenue | -135% | -100% | 8% | -29% | 16% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- Can it pay its interest? -16.6×Does not cover its interestOperating income ($7M) ÷ interest expense $429K
What this means
A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.
- Net cashCash $28M − debt $649K
What this means
Cash and short-term investments exceed every dollar of debt by $28M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 299 + DIO 319 − DPO 204 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Below average through the cycle8-yr median, range -719%–82%; -258% latest = NOPAT ($6M) ÷ invested capital $2MIndustry peers: median -79%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 8 years (it ran -258% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- Consumes cash through the cycle8-yr median margin, range -135%–21%; latest ($4M) = operating cash ($4M) − maintenance capex $2KIndustry peers: median -1308%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -353% of revenue this year, a -4% median across 8 years.
- Loss, and burning cashNet income ($4M) · cash from operations ($4M)
What this means
The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.
How is the cash used?
- Not enough data
What this means
The filing data didn't include the inputs for this check.
- Investing or harvesting? 0.03×HarvestingCapex $2K ÷ depreciation $74K
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 2 of 6 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $1M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 7.93×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt PassDebt ≤ working capital · $649K vs $30M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (10-yr record) · 7 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record MissUninterrupted dividends · none paid
What this means
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth MissEarnings +33% over the record · −422%
What this means
At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-4.39/share (latest year $-4.32), the averaged base the calculator's gate runs on, and book value is $31.01/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2017–2026
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 3 of 10
What this means
Lost money in 7 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 1 of 6 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 27% → −303% (3-yr avg ends)
What this means
Through the cycle the operating margin slipped — about 27% early to −303% lately, median −130% — competition or costs are biting in.
- Reinvestment, incremental ROIC returns capital
What this means
The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.
- Worst year 2026 · −625.9% op. margin
What this means
Operations went underwater in 2026, understand why before trusting the good years.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product.
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of fiscal year-end, Mar 31, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$28M
- Receivables$932K
- Inventory$777K
- Other current assets$5M
- Debt due within a year$4K
- Accounts payable$498K
- Other current liabilities$4M
From the company's latest filing.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| DNTHDianthus Therapeutics Inc. | $2M | — | -1704.7% | -54% | -1308% |
| ORMPOramed Pharmaceuticals Inc. | $2M | 1% | -754.4% | -29% | -479% |
| INBXInhibrx Biosciences Inc. | $1M | — | -12178.9% | — | -10806% |
| SXTCChina SXT Pharmaceuticals Inc. | $1M | 48% | -88.2% | -58% | -1% |
| STTKShattuck Labs Inc. | $1M | — | -1408.3% | -104% | -1059% |
| SLNSilence Therapeutics PLC | $559K | 60% | -242.7% | -177% | -211% |
| QUCYQuantum Cyber N.V. | $537K | 73% | -3005.0% | — | -2045% |
| MREOMereo BioPharma Group plc | $500K | — | -8021.4% | — | -6198% |
| Group median | — | 54% | -1556.5% | -58% | -1184% |
The price
What a price has to assume.
What the price implies
reverse-DCFEnter the US price, in dollars: the NYSE/Nasdaq quote you hold. China SXT Pharmaceuticals Inc.'s US listing is the ordinary share itself. The record tables elsewhere on this page remain as filed.
China SXT Pharmaceuticals Inc. is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.
Revenue, delivered−21%/yr’21→’26
Enter a price to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.
Manual order: ← SVREW its page in the Manual SY →
Industry order: ← SVRA the Pharmaceuticals chapter TAK →